Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Aditxt Inc
ADTX
Healthcare
Biotechnology
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women’s health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a...
nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:ADTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 28, 2025 8:15am
New Press Release - Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
The event will begin today at 11:30 a.m. ETEvent to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University Aditxt, Inc. (NASDAQ: ADTX...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 24, 2025 8:30am
New Press Release - Evofem Reports Fourth Consecutive Year of Net Sales Growth
-- 2024 Net Sales Increased 6% to $19.4 Million ---- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense ---- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 24, 2025 8:15am
New Press Release - Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
Acquisition is key to Pearsanta’s mission of addressing cancer through early detection and preventionPearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA/CAP-certified monitoring center and laboratories Aditxt, Inc...
read article.
(217)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Mar 20, 2025 11:14am
Sold out of this stock yesterday.
It was my mistake for selling it too soon,but I didn't know that it was going to go up more today and didn't want to be too greedy with it either,but it was a big return for me,so that there
...more
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 19, 2025 9:29am
ADTX....Shelf on the table
Dilution mode Just sayin
(217)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Mar 18, 2025 4:30pm
Using technical analysis for this stock.
Bought it early this morning in the pre market for $4.43 cents per share and sold out of it at lunchtime for $9.87 cents per share,so that was good enough for me anyway.Wow.
(217)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Mar 18, 2025 8:02am
Buy buddy buy because it's taking off this morning.
Otherwise you guys out there will be left behind by the markets
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 18, 2025 7:23am
New Press Release - Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Four new funding proposals, totalling US$117.5 million, have been submitted for review Modifications received to U.S. Air Force Academy Cooperative Agreement Outside date for going-private transaction extended to March 31, 2025HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 17, 2025 8:16am
New Press Release - Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025
Evofem CEO Saundra Pelletier will join Aditxt Co-founder and CEO Amro Albanna to discuss status and future plans Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 12, 2025 4:17pm
New Press Release - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, announced today that it will effect a 1-for-250 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 06, 2025 8:15am
New Press Release - Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) and its progress in advancing ADI-100, an investigational product candidate to be...
read article.
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 21, 2025 2:18pm
ADTX....Almost down to where the Pump started
Sub 10 cents now Who's gonna be a hero?
(657)
•••
Iseneschal
X
Comment by
Iseneschal
on Feb 20, 2025 9:10am
RE:ADTX ....gettin the ST pump workin it
Looks like the ST Pump is broken and you can all say I've been had .... AGAIN !!!!
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 18, 2025 7:58pm
ADTX ....gettin the ST pump workin it
over 14 cents on big volume during AH trading
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 19, 2024 7:18am
New Press Release - Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESCourt’s approval allows transaction with Aditxt to proceed, subject to other closing conditionsHALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink...
read article.
Prev
1
2
3
4
5
6
7
8
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Podcasts